147 related articles for article (PubMed ID: 11812597)
21. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
22. Weight-based ribavirin with pegylated interferon alfa 2b: benefits, risks, and the origin of the evidence.
Hrachovec J; Patel P
Gastroenterology; 2003 Jun; 124(7):2003-4; author reply 2004-5. PubMed ID: 12812198
[No Abstract] [Full Text] [Related]
23. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.
Baker DE
Rev Gastroenterol Disord; 2003; 3(2):93-109. PubMed ID: 12776006
[TBL] [Abstract][Full Text] [Related]
24. Pegylated interferon alfa-2b (peg-intron) plus ribavirin (rebetol) in the treatment of chronic hepatitis C: a local experience.
Seow EL; Robert Ding PH
Med J Malaysia; 2005 Dec; 60(5):637-41. PubMed ID: 16515116
[TBL] [Abstract][Full Text] [Related]
25. [Effectiveness of long-acting interferon (peginterferon)].
Kondo Y; Tateishi R; Yoshida H; Omata M
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):515-8. PubMed ID: 15359853
[No Abstract] [Full Text] [Related]
26. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant.
Rendina M; Schena A; Castellaneta NM; Losito F; Amoruso AC; Stallone G; Schena FP; Di Leo A; Francavilla A
J Hepatol; 2007 May; 46(5):768-74. PubMed ID: 17383045
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden.
Bernfort L; Sennfält K; Reichard O
Scand J Infect Dis; 2006; 38(6-7):497-505. PubMed ID: 16798701
[TBL] [Abstract][Full Text] [Related]
28. [Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C].
Lee HJ; Eun JR; Choi JW; Kim KO; Moon HJ
Korean J Hepatol; 2008 Mar; 14(1):46-57. PubMed ID: 18367857
[TBL] [Abstract][Full Text] [Related]
29. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
MMW Fortschr Med; 2002 Sep; 144(38):59. PubMed ID: 12395712
[No Abstract] [Full Text] [Related]
30. Peginterferon and ribavirin for hepatitis C.
Leiner S
N Engl J Med; 2007 Mar; 356(12):1270; author reply 1271. PubMed ID: 17380577
[No Abstract] [Full Text] [Related]
31. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
32. [Peginterferon alfa-2b and ribavirin-induced pure red cell aplasia during treatment of chronic hepatitis C treated by cyclosporin A with good response].
Kato M; Ryu T; Miura H; Yamada H; Saito T
Nihon Naika Gakkai Zasshi; 2008 Jul; 97(7):1678-80. PubMed ID: 18681159
[No Abstract] [Full Text] [Related]
33. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
Hasan F; Al-Khaldi J; Asker H; Al-Ajmi M; Owayed S; Varghese R; Siddique I; Al-Nakib B
Antivir Ther; 2004 Aug; 9(4):499-503. PubMed ID: 15456080
[TBL] [Abstract][Full Text] [Related]
34. [Peginterferon alpha and ribavirin therapy for difficult-to-treat chronic hepatitis C patients].
Pawłowska M; Halota W
Przegl Epidemiol; 2002; 56 Suppl 4():51-4. PubMed ID: 14750261
[No Abstract] [Full Text] [Related]
35. Treatment of chronic hepatitis C patients with combination of alpha-interferon and ribavirin, consensus and pegylated interferons.
Husa P; Husova L
Bratisl Lek Listy; 2001; 102(5):248-52. PubMed ID: 11725377
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of peginterferons.
Zeuzem S; Welsch C; Herrmann E
Semin Liver Dis; 2003; 23 Suppl 1():23-8. PubMed ID: 12934165
[TBL] [Abstract][Full Text] [Related]
37. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.
Mangia A; Santoro R; Minerva N; Ricci GL; Carretta V; Persico M; Vinelli F; Scotto G; Bacca D; Annese M; Romano M; Zechini F; Sogari F; Spirito F; Andriulli A
N Engl J Med; 2005 Jun; 352(25):2609-17. PubMed ID: 15972867
[TBL] [Abstract][Full Text] [Related]
38. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4.
Alfaleh FZ; Hadad Q; Khuroo MS; Aljumah A; Algamedi A; Alashgar H; Al-Ahdal MN; Mayet I; Khan MQ; Kessie G
Liver Int; 2004 Dec; 24(6):568-74. PubMed ID: 15566506
[TBL] [Abstract][Full Text] [Related]
39. Peginterferon and dose-titrated ribavirin for hepatitis C-associated nephrotic membranoproliferative glomerulonephritis type 1.
Orlent H; Mathot RA; Van Bommel EF; Vulto AG; Schalm SW; Brouwer JT
Dig Dis Sci; 2005 Oct; 50(10):1804-6. PubMed ID: 16187177
[No Abstract] [Full Text] [Related]
40. [Patient, 50, with chronic hepatitis C genotype 1 infection. Therapeutic success despite poor prognosis].
Klinker H
MMW Fortschr Med; 2003 Oct; 145(41):39-40. PubMed ID: 14655480
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
